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ABSTRACT 
The synthesis and crystallisation of the pharmaceutically important metabolite, paracetamol-
O-glucuronide, is described.  Hydrated and anhydrous forms of the target molecule have been 
characterised by PXRD, DSC and TGA.  In addition, a methanol solvate has been analysed, 
including single crystal analysis, which represents the first structure solution for this system.  
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Glucuronides are a group of biologically active molecules formed in vivo as a result of phase 
II metabolism.1  This metabolic pathway is primarily concerned with the bioconjugation of 
non-polar xenobiotics to glucuronic acid resulting in more water soluble forms of the parent 
compound which then can be readily excreted.  For example, paracetamol, one of the world’s 
most widely used analgesic and antipyretics, is metabolized extensively in the body, mainly 
in the liver.  The main metabolites from this pathway are paracetamol-O-sulfate, N-acetyl-p-
benzoquinone imine and paracetamol-O-glucuronide 5.  Formation of paracetamol-O-
glucuronide accounts for up to two thirds of this metabolic pathway.2 
Glucuronides are highly polar molecules which have traditionally been synthesized on 
milligram scales for the purposes of pharmacological testing, testing for drug substances of 
abuse and investigation of possible metabolites of new APIs during clinical trials.3  Many 
synthetic methods exist for the synthesis of O-linked glucuronides and their various 
derivatives.  Acyl protected intermediates such as methyl tetra-O-acetyl-β-D-
glucopyranuronate 1 seem to be the most prevalent intermediates for the synthesis of the 
glucuronide series, although higher priority alkyl and aryl protecting groups such as the iso-
butyryl  ,4 pivaloyl5 and benzyl6 groups have also been employed.   
Based on Etter's rules,7 the ratio of hydrogen bond donors : acceptors for a typical 
glucuronide suggest that it is possible to incorporate one or more hydrate or solvate molecule 
within the hydrogen bonding framework in the solid state.8,9  This guideline for the formation 
of hydrates and solvates is in agreement with Etter’s rules.9  Hydrate forms of both the parent 
acid and sodium salt of paracetamol-O-glucuronide 5 have been reported10,11 as well as an 
anhydrous form.12  To date no solid state forms of this biologically important molecule have 
been fully elucidated.  Herein we report the preparation, crystallisation and crystal forms of 
4-acetomidophenyl-β-D-glucopyranosiduronic acid 5 (Scheme 1) and for the first time the 
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crystal structure of a methanol solvate of the target compound.  The only reported crystal 
structures of a glucuronide is that of estrone glucuronide.13  (CSD14 ref. code RESKAB) 
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Scheme 1. (a) Bu3SnOMe, CH2Cl2, 87%; (b) CCl3CN,DBU, CH2Cl2, 65%; (c) paracetamol, 
BF3.Et2O, CH2Cl2, 76%; (d) 2 eq. K2CO3 in 5:5:1 MeOH:THF:H2O, followed by 
Amberlyst® 15 H+ ion exchange resin, 47% (for sodium salt, Amberlyst® 15 H+ resin, then 
aq. NaHCO3 soln, MeOH, 85%). 
 
A number of syntheses of compound 5 have been reported.10, 12, 15  Brown et al15 used a tri-O-
isobutyryl protected trichloroacetimidate as glucuronidating agent.  However, we found that 
use of the tri-O-acetyltrichloroacetimidate 316 provided the most practical route to useful 
quantities of compound 5 (Scheme 1).  Treatment of methyl tetra-O-acetyl−β-D-
glucopyranuronate 1 with tributyltin methoxide in dichloromethane17 yielded the hemiacetal 
2 as a mixture of diastereoisomers (approximately 75:25 α:β) in 87% yield.  Coupling 2 to 
trichloroacetonitrile with DBU resulted in the exclusive formation of the α-imidate 3.  
Methyl (4-acetamidophenyl-2,3,4-tri-O-acetyl-β-D-glucopyranosid)uronate 4 was obtained 
using the glucuronide donor 3, paracetamol and BF3.OEt2 in dichloromethane.  Base 
hydrolysis of 4 was achieved using 2 equivalents of K2CO3 in 5:5:1 MeOH:THF:H2O.18  
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Following neutralisation with a strongly acidic ion-exchange resin and column 
chromatography, 4-acetomidophenyl-β-D-glucopyranosiduronic acid 5 was isolated in 47% 
yield.  A coupling constant of 7.5Hz for the 1H doublet was assigned to the hydrogen on C-1 
of the glucopyranose, indicative of β stereochemistry, which was also confirmed by single 
crystal analysis (see below). 
In our hands, complete evaporation to dryness of solutions of 5 gave amorphous material, 
displaying typical amorphous halos in their powder X-ray diffraction (PXRD) patterns.  
Attempts to crystallize these batches from solvents also gave amorphous material.  
Crystalline material could be obtained by clarifying the product solution with charcoal, 
reducing to approximately half volume and cooling to between 0-5 °C.  This resulted in the 
formation of two distinct crystalline forms of target compound 5, an anhydrous form and a 
hydrated form.  The anhydrous form of 5 was characterised by PXRD (Supplementary 
Information) and shows no significant weight loss in the corresponding TGA traces 
(Supplementary Information).  The other crystalline form of 5 was isolated as a monohydrate 
with a needle-like habit (Supplementary Information).  The TGA traces (Figure 1) revealed 
two events, the first in the region of 20-60 °C which is due to residual solvent tightly held on 
the crystal surfaces, the second in the region of 100-120 °C, being due to the hydrate.  On no 
occasion was both of these forms observed together.  Concomitant polymorphism, in which 
two or more crystal forms are observed to be present simultaneously, is well reported19.  
Formation of either one particular form or another, but not both simultaneously, as observed 
in this case, is more unusual but still would not be a particularly surprising crystallisation 
phenomenon.  It is likely that sub-critical nuclei of both forms are present in solution but that 
once one form nucleates, growth of that form is exclusive at least on the occasions these 
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crystallisation have carried out by us.  There was no obvious difference in how these 
crystallisations were carried which would lend a bias toward one form or the other. 
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Figure 1: TGA Trace 5.H2O. 
 
 
The crystalline sodium salt of 5 was achieved by reaction of the free acid with aqueous 
sodium bicarbonate in ethanol.  However, recrystallisation of the sodium salt from aqueous 
ethanol yields microcrystalline 5 sodium salt as an agglomerated solid which was not suitable 
for structural analysis.  
The only form observed in our studies suitable for single crystal analysis was a methanol 
solvate of 5 which was crystallized from methanol-dichloromethane.  This form was found to 
be orthorhombic, crystallizing in the P212121 space group (See Table 1).  Comparison of the 
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PXRD pattern of the bulk material with the theoretically generated pattern based on the 
crystal structure we have obtained shows that the structure is representative of the bulk 
material (Supplementary Information). 
 
 
Table 1: Crystal data for 5.MeOH.  
Chemical formula C15H21NO9 
Formula Mass 359.33 
Crystal system Orthorhombic 
a/Å 8.3590(4) 
b/Å 8.4792(4) 
c/Å 22.8663(10) 
Unit cell volume/Å3 1620.71(13) 
Temperature/K 296(2) 
Space group P212121 
No. of formula units per unit cell, Z 4 
Radiation type CuKα (1.5418 Å) 
Absorption coefficient, μ/mm-1 1.054 
No. of reflections measured 12824 
No. of independent reflections 2699 
Rint 0.032 
Final R1 values (I > 2σ(I)) 0.033 
Final wR(F2) values (I > 2σ(I)) 0.085 
Final R1 values (all data) 0.038 
Final wR(F2) values (all data) 0.088 
Goodness of fit on F2 1.03 
Flack parameter 0.3(2) 
 
 
 
Face indexing experiments of the needle-like crystals observed for the methanol solvate 
indicate that the preferred growth direction is along the b axis of the unit cell (Figure 2). 
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Figure 2: Lattice orientation of 5.MeOH showing preferential growth along the 
crystallographic b axis. 
 
 
This can be rationalised by inspection of the single crystal data which shows C(5) chains7 
along the crystallographic b axis (Figure 3).  These C(5) chains are made by the diol 
functionality on C-2 and C-3 of the glucopyranose ring, and are related by a 21 screw axis as 
represented in Figure 3.  Unitary graph set analysis7 along this crystallographic axis shows a 
discrete (capping) H------O-Me hydrogen bond between the OH group on C-4 of the 
glucopyranose ring and the interstitial MeOH molecule is also observed (Figure 3). 
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Figure 3: (a) Unit cell of 5.MeOH along the crystallographic b axis, showing C(5) chains and 
interstitial MeOH molecules, along the preferential growth axis (some molecules have been 
removed for clarity). (b) Graphical representation of the C(5) chains along the b axis of unit 
cell. 
 
 
1. Experimental 
1.1. General 
All commercial reagents were purchased from Sigma-Aldrich and were used without further 
purification.  All solvents were either of a HPLC grade or distilled prior to use.  Methyl tetra-
O-acetyl-β-D-glucopryranuronate 1 was prepared as described by Bollenback et al.20  Thin 
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layer chromatography (TLC) was conducted on coated silica plates (Merck silica gel 60, 
F24).  Column chromatography was conducted using Merck silica gel 60, typically with a 
30:1 ratio of silica to sample.  TLC plates were visualized either under ultraviolet (UV) light 
or an anisaldehyde stain.  Infrared spectra were recorded on a Perkin-Elmer Paragon 1000 
FT-IR spectrometer.  The 1H NMR spectra were recorded on a Bruker AVANCE 300 MHz or 
400 MHz spectrometers.  Spectra were recorded using either deuterated chloroform (CDCl3), 
deuterated dimethyl sulfoxide (d6-DMSO) or deuterated water (D2O) using tetramethylsilane 
as the internal standard. Chemical shift values (δH and δC) are expressed as parts per million 
(ppm).  Elemental analyses were performed by the Microanalysis Laboratory, University 
College Cork, using a Perkin-Elmer 240 and an Exeter Analytical CE440 elemental analyzer.   
 
1.2. Synthesis 
1.2.1. Methyl 2,3,4-triacetyl-α,β-glucopyranuronate (2) 
Methyl tetra-O-acetyl-β-D-glucopryranuronate (1) (15.0 g, 39 mmol) was dissolved in dry 
CH2Cl2 (120 mL) and tributyltin methoxide (12.6 mL, 43.8 mmol) was added.  The solution 
was refluxed for 4 h until TLC indicated consumption of the starting material.  The solution 
was cooled to room temperature and then washed with 10% aq HCl (2 x 20 mL), water (20 
mL), dried and concentrated in vacuo.  The resulting syrup was trituated with hexane (3 x 40 
mL) to yield a solid which was recrystallised from EtOAc:hexane to give a white crystalline 
solid (11.6 g, 87%) ratio of α to β anomers (by 1H NMR) = 75:25 (α:β) mp 89-90 °C, lit.21 
91-92 °C;  IR (KBr) ν   3469 (O-H) 2958 (C-H) 1752 (C=O) cm-1;  m/z (ESI): 357 (M++ Na, 
15%). 1H NMR (CDCl3) (α anomer) δ 5.57 (t, 1H, J 9.5 Hz, H-3), 5.54 (d, 1H, d, J 3.6 Hz, 
H-1),  5.17 (t, 1H, J 9.5 Hz, H-4), 4.90 (dd, 1H, J 3.6, 9.5 Hz, H-2), 4.59 (d, 1H, J 9.5 Hz, H-
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5), 4.24 (br d, 1H, J 3.6 Hz, OH) 3.75 (s, 1H, CO2Me), 2.09 (s, 3H, OAc), 2.04 (s, 3H, OAc),  
2.03(s, 3H, OAc). 13C NMR (CDCl3) (α anomer) δ 170.2 (C=O), 170.1 (C=O), 168.5 (C=O), 
166.7 (C=O), 90.2 (C-1), 70.78 (C-H), 69.6 (C-H), 69.2 (C-H), 67.99 (C-H), 52.90 
(CO2CH3), 20.6 (3 x OAc). 1H NMR (CDCl3) (β anomer) δ 5.29 (t, 1H, J 9.5 Hz), 5.21 (t, 
1H, J 9.5 Hz), 4.95 (d, 1H, J 7.8 Hz, H-1),  4.82 (t, 1H, J 9.3 Hz), 4.36 (br d, 1H, J 7.8 Hz, 
OH), 4.12 (d, 1H, J 9.6 Hz, H-5), 3.76 (s, 3H, CO2Me), 2.09 (s, 3H, OAc), 2.04 (s, 3H, 
OAc), 2.03 (s, 3H, OAc). 13C NMR (β anomer) δ 170.52 (C=O), 170.10 (C=O), 169.59 
(C=O), 167.61 (C=O), 95.45 (C-1), 72.85 (C-H), 72.53 (C-H), 71.6 (C-H), 69.43 (C-H), 
53.10 (CO2CH3), 20.51 (3 x OAc). Anal . Calcd forC13H18O10: C, 46.71; H, 5.43. Found: C, 
46.36; H, 5.70. 
1.2.2. Methyl 2,3,4-triacetyl-1-O-(trichloroacetimidoyl)-α-D-glucopyranouronate (3) 
Methyl 2,3,4 triacetyl-α,β-glucopyranuronate (2) (12.0 g, 36 mmol) and trichloroacetonitrile 
(18 mL, 180 mmol) was stirred in dry CH2Cl2 at 0 °C for 30 min.  DBU (1.5 mL, 10 mmol) 
was added dropwise and the solution was allowed warm to room temperature and stirred 
overnight.  The solvent was removed in vacuo and the residue was subjected to flash 
chromatography (40:59:1 EtOAc: hexane: Et3N).  Appropriate fractions were pooled and the 
solvent removed under reduced pressure to yield a syrup which was triturated with diethyl 
ether.  Following recrystallisation with EtOAc:hexane (50:50) to yield 8.5g (65%) of an off 
white solid. mp 108-109 °C, lit.21 109-110 °C; IR (KBr) ν  3320 (N-H), 2958 (C-H), 1755 
(C=O) cm-1.  1H NMR (CDCl3) δ 8.73 (s, 1H, NH), 6.64 (d, 1H, J 3.6 Hz, H-1), 5.63 (t, 1H, J 
10 Hz, H-3 ), 5.27 (t, 1H, J 10 Hz, H-4 ), 5.16 (dd, 1H, J 3.6 Hz, 10 Hz, H-2), 4.49 (d, 1H, J 
10 Hz, H-5), 3.75 (s, 3H, CO2Me), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.02 (s, 3H, OAc). 
13C NMR (CDCl3) δ 169.78 (C=O), 169.72 (C=O), 169.47 (C=O), 167.14 (C=O), 160.58 
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(C=N), 92.64 (C-H), 70.49 (C-H), 69.47 (C-H), 69.10 (C-H), 68.96 (C-H), 53.04 (CO2Me), 
21.04, 20.66, 20.48, 20.39 (3 x OAc and 1 x CCl3). 
1.2.3. Methyl (4-acetamidophenyl-2,3,4-tri-O-acetyl-β-D-glucopyranosid)uronate (4) 
Methyl 2,3,4-triacetyl-1-O-(trichloroacetimidoyl)-α-D-glucopyranouronate (3) (10.0 g, 21.0 
mmol), paracetamol (3.5 g, 23 mmol) and 4Å molecular sieves were stirred in dry CH2Cl2 
for 30min.  BF3.Et2O (4 mL, 23 mmol) was added dropwise at 0 °C and the solution was 
allowed to stir overnight.  The solvent volume was reduced, washed with sat. aq Na2CO3 (2 x 
30mls), water (2 x 30ml) dried with MgSO4 and concentrated in vacuo to yield a pale white 
solid.  Column chromatography (40:1 CHCl3:MeOH) followed by recrystallisation from IPA 
gave a white crystalline solid (7.5g, 76%). mp 214-216 °C, lit.23  213.5-214.5 °C; IR (KBr) ν 
3300 (N-H), 3146-2969 (C-H), 1758 (C=O), 1509 (Ar-H) cm-1. m/z (ESI): 468 (M+, 100%) 
1H NMR (CDCl3) δ 7.42 (d, 2H, J 9 Hz, Ar-H), 7.2 (br s, 1H, NH), 6.96 (d, 2H, J 9 Hz, Ar-
H), 5.35-5.23 (m, 3H, H-2, 3, 4), 5.07 (d, 1H, J  7.2 Hz, H-1), 4.14 (d, 1H, J 9.6 Hz, H-5), 
3.74 (s, 3H, CO2Me), 2.16 (s, 3H, NAc), 2.06 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, 
OAc). 13C NMR (CDCl3) δ 170.08 (C=O), 169.35 (C=O), 169.25 (C=O), 168.29 (C=O), 
166.91 (C=O), 153.28 (Cq, Ar) 133.28 (Cq, Ar), 121.66 (C-H, Ar), 117.82 (C-H, Ar), 99.64 
(C1-H), 72.62 (C-H), 71.91 (C-H), 71.1 (C-H), 69.16 (C-H), 52.97 (CO2Me), 24.37 (NHAc), 
20.75, 20.6, 20.49 (3 x OAc). 
1.2.4. Acetamidophenyl-β-D-glucopyranosiduronic Acid (5) 
Methyl (4-acetamidophenyl-2,3,4-tri-O-acetyl-β-D-glucopyranosid)uronate (4) (1.00 g, 2.15 
mmol) was dissolved in a solution of MeOH: THF: H2O (5:5:1, 40-50 mL) and allowed to 
stir under an nitrogen atmosphere at 0 °C.  K2CO3 (0.6g, 4.3mmol) was added and the 
reaction mixture was heated to 40 °C for 5h.  The reaction mixture was cooled to room 
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temperature and neutralized with strongly acidic ion exchange resin (Amberlyst® 15 H+ 
Form).  The exchange resin was removed and the solution clarified with charcoal.  The 
solvent volume was removed in vacuo and the residue subjected to column chromatography 
using EtOAc:MeOH:H2O (60:30:10).  Appropriate fractions were pooled and the solvent 
removed in vacuo.  Recrystallisation of the residue yielded 0.34g (47%) of crystalline 
material. mp 135 °C (MeOH:CH2Cl2), lit.15 134-137 °C; IR (KBr) ν  3347 (O-H), 2925 (C-
H), 1728 (C=O), 1663 (C=C), 1510 (C=C) cm-1. m/z (ESI): 328 (M+, 10%), 326 (M-, 20%). 
1H NMR (d6-DMSO) δ 9.89 (s, 1H, NH), 7.52 (d, 2H, J 8.8 Hz, Ar-H), 7.02 (d, 2H, J 8.8 Hz, 
Ar-H), 5.41 (br s, 1H, OH) 5.22 (br s, 1H, OH), 4.92 (d, 1H, J 7.5 Hz, H-1), 4.42 (br s, 1H, 
OH), 4.17(br s, 1H, OH), 2.06 (s, 3H, NAc). δH (D2O shake) 7.25 (d, 2H, J 9Hz, Ar-H), 7.03 
(d, 2H, J 9Hz, Ar-H), 5.06 (d, 1H, J 7.5Hz, H-1), 4.06 (d, 1H, J 9Hz, H-5), 3.64-3.53 (m, 3H, 
H-2, 3, 4), 2.04 (s, 3H, NAc). 13C NMR (D2O) δ 172.7 (C=O), 171.9 (C=O), 153.8 (Cq), 
132.18 (Cq), 123.7, 117.2, 100.4 (C-H), 75.0 (C-H), 74.5 (C-H), 72.5 (C-H), 71.1 (C-H), 
23.7 (NHCOCH3). 
 
1.2.5. 4-Acetomidophenyl-β-D-glucopyranosiduronic acid (5) sodium salt. 
Methyl (4-acetamidophenyl 2,3,4-tri-O-acetyl-β-D-glucopyranosid)uronate (4) (1.00 g, 2.15 
mmol) was dissolved in a solution of MeOH: THF: H2O (5:5:1, 40-50 mL) and the solution 
stirred under an N2 atmosphere at 0 °C.  K2CO3 (0.6g, 4.3mmol) was added and the reaction 
mixture was heated to 40 °C for 5h.  The reaction mixture was cooled to room temperature 
and neutralized with strongly acidic ion exchange resin (Amberlyst® 15 H+ Form).  The 
exchange resin was removed and the solution was clarified with charcoal.  After removal of 
the charcoal on a bed of Celite® the solvent was removed and the residue was dissolved in 
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MeOH (50 mL).  Aq. NaHCO3 solution (20 ml) was added and the solution heated to boiling.  
After heating for 10 min. the solution was allowed to cool to room temperature and left to stir 
for 1 h.  The resulting solid was isolated and recrystallised from aq. EtOH to give the product 
as a white crystalline solid 0.63 g (85% yield).  mp 220-230 °C, (decomp.). IR (KBr) ν  3298 
(O-H), 2935 (C-H), 1578 (C=O) , 1510 (C=C), 1414 (C=C), 1043(C-O) cm-1; 1H NMR (D2O) 
δ 7.36 (d, 2H, J 9.2Hz, Ar-H), 7.14 (d, 2H, J 9.2Hz, Ar-H), 5.10 (d, 1H, J 6.8Hz, H-1), 3.89 
(d, 1H, J 9.6Hz, H-5), 3.64-3.55 (m, 3H, H-2, 3, 4), 2.16 (s, 3H, NAc). 
 
1.3. Crystal Growth 
1.3.1. Hydrated and anhydrous forms.  Crystalline 5 was obtained as follows.  Following 
neutralization of the reaction mixture with acidic ion exchange resin, removal of the resin and 
clarification of the solution with charcoal, the filtered solution was reduced to approximately 
half volume and cooled to between 0-5 °C.  This procedure provided either the hydrate or the 
anhydrous form of compound 5 with no obvious bias towards either.  Mixtures of the two 
forms were not observed on any occasion. 
1.3.2. Amorphous Form.  Amorphous 5 was obtained by allowing a saturated solution of 
paracetamol-O-glucuronide, from a variety of solvents, including MeOH, EtOH and H2O, to 
slowly evaporate at room temperature. 
1.3.3. MeOH Solvate.  Compound 5 (100 mg) was suspended in a minimum of 
dichloromethane (approx 10 mL), a minimum of hot methanol (approx 5-6 mL) was added to 
affect dissolution, and following cooling and slow evaporation of the solvent crystalline 5 
was isolated with a needle-like crystal habit. 
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1.3.4. Sodium Salt.  Compound 5 sodium salt (200 mg) was completely dissolved in a 
minimum of aqueous ethanol (approx 15 mL) and following cooling and slow evaporation of 
the solvent microcrystalline 5 sodium salt was isolated as an aggregated solid. 
 
1.4. Solid state characterisation 
DSC was performed using a TA Q1000 DSC with RSC 40 cooling system.  The sample was 
placed into an aluminum DSC pan, and the weight accurately recorded.  The pan was covered 
with a lid and then crimped.  The sample cell was heated under a nitrogen purge at a rate of 5 
°C min-1, from 25 °C up to a final temperature of 160 °C.  TGA analysis was performed using 
a TA Instruments Q500 thermogravimetric analyzer.  The sample was placed in an aluminum 
sample pan and inserted into the TG furnace.  The furnace was heated under nitrogen at a rate 
of 5 °C min−1 from 25 °C up to a final temperature of 160 °C.  Single-crystal X-ray 
diffraction measurements were made on a Bruker APEX II DUO diffractometer using 
graphite monochromatized CuKα (1.5418 Å).  All calculations were made using the APEX2 
v2009.3-0 software24,25 and the diagrams prepared using Mercury.26 
 
1.5 Supplementary data 
Complete crystallographic data for the structural analysis have been deposited with the 
Cambridge Crystallographic Data Centre, CCDC number 841974. Copies of this information 
may be obtained free of charge from the Director, Cambridge Crystallographic Data Centre, 
12 Union Road, Cambridge, CB2 1EZ, UK. (fax: +44-1223-336033, e-mail: 
deposit@ccdc.cam.ac.uk or via: www.ccdc.cam.ac.uk).  PXRD data on the crystalline forms 
and TGA data on the anhydrous forms are also provided. 
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